Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

Background: Recent clinical trial results reported that stereotactic radiotherapy (SABR) may improve survival for patients with oligometastatic (OM) cancer. Given that these results come from a phase II trial, there remains considerable uncertainty about this finding, and about the cost-effectivenes...

Full description

Bibliographic Details
Main Authors: Adam J. N. Raymakers, David Cameron, Scott Tyldesley, Dean A. Regier
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Current Oncology
Subjects:
cost-effectiveness analysis
cost-utility analysis
economic evaluation
radiotherapy
SABR
health technology assessment
Online Access:https://www.mdpi.com/1718-7729/28/3/172

Internet

https://www.mdpi.com/1718-7729/28/3/172

Similar Items